Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Claret Capital Partners invests €28M in Cinclus Pharma
Claret Capital Partners invests €28M in Cinclus Pharma Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases Claret Capital Partners providing growth funding of…
Pharma Foods Intl 1H Loss Y1.82B Vs Net Y229.00M
Pharma Foods International Co. Ltd. (2929.TO) Japan Half-Year Ended January 31 GROUP 2026 2025 Revenue Y32.44 bln Y29.86 bln Operating Profit (Y2.36 bln) Y623.00 mln Pretax Profit (Y2.44 bln) Y645.00 mln Net Profit (Y1.82 bln) Y229.00 mln Per share…
Rapid Micro Biosystems: Big Pharma Adoption Driving Growth (NASDAQ:RPID)
Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers…
TrumpRx Is a Step Toward Making the Pharma Market Finally Work for America
The Trump administration's latest move appears to continue its promise to put America first. Americans have long paid the highest drug prices in the world, while patients in Europe and Canada receive the same medicines for a fraction of the cost.
The conditions are just right for this dividend-paying pharma stock as it mounts a comeback
When poring over charts this week I wanted to find a stock with low risk, a safe dividend and a potential reversal brewing. With every search I kept coming back to this one – Pfizer. It's a stock that has driven investors crazy over the…
Royalty Pharma PLC $RPRX Shares Bought by Korea Investment CORP
Korea Investment CORP increased its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 39.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor…
The president brands his own healthcare reform
“This is a very big deal. People are going to save a lot of money and be healthy,” Trump said in a press conference that day. But how big a deal is it, in terms of the overall healthcare industry in America? The Washington Examiner…
Trump's MFN policy threatens US competitiveness with China
The two most recent examples of this tendency are the MFN proposals advanced by the administration and introduced in Congress last spring. These plans are successors to two earlier initiatives from the first Trump administration and are similar in…
Kodak outlines post-pension reversion growth as 2025 operational EBITDA rises 144% (NYSE:KODK)
Kodak achieved a net positive cash position, reduced debt by $303 million, and significantly lowered interest expenses with $337 million in unrestricted cash, marking the strongest balance sheet in many years. Growth is driven by new product…
Vivek Ramaswamy's chances of losing in Ohio governor race-Poll
Republican candidate for governor in Ohio, Vivek Ramaswamy, trails Democrat Amy Acton by 10 points, a new poll from EMC Research, Inc., shows on Thursday. Newsweek reached out to political analysts via email for comment. Ohio has not elected a…
Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November
Eli Lilly is rated Sell/Avoid due to extreme overvaluation and waning technical momentum, despite robust GLP-1-driven growth. LLY trades at 29x trailing EV/EBITDA and 23.7x forward 2027 P/E estimates—both materially above Big Pharma medians.
AI policy's new power center
The Pentagon is turning procurement into policy, staking its claim as Washington's most powerful AI player with its decision to ditch Anthropic. Why it matters: As lawmakers debate guardrails, the Pentagon showed how it can reshape the AI industry…
Europe's second chance on AI: building an opportunity in factories, labs, and the real economy
For much of the last three decades, Europe has played a back-footed role in the digital economy: influential in regulation, strong in research, but rarely the place where globally dominant technology companies are built. The internet era created…
The synthetic opioid 10x stronger than fentanyl and popping up across states
Multiple states are ringing the alarm over cychlorphine, the latest synthetic opioid pervading the U.S. illicit drug supply. Like fentanyl, most opioid addicts aren't aware they're taking cychlorphine when buying off the streets, but this drug is…
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's disease NLRP3 inhibitor ACI-19764 Phase 1 trial…
Receive a Daily briefing on Pharma Industry News
Get Started